EB66® partnered human programs
Valneva's EB66® cell line is a testament to the advancement of vaccine manufacturing technology and constitute a unique and revolutionary alternative for the cost-effective production of vaccines currently produced in eggs or in chicken embryonic fibroblasts.
EB66® is one of the most extensively studied and characterized cell lines available for human vaccine development and is currently under evaluation by many organizations in the human vaccine industry for the production of new viral vaccines.
A landmark to the success of the efforts in developing EB66® cells has resulted in the approval of a pandemic influenza vaccine for human use.
In March 2014, Valneva announced the first ever marketing approval for a human vaccine produced in the EB66® cell line. The approval was granted by the Japanese health authorities to the Chemo-Sero Therapeutic Research Institute (Kaketsuken), a co-development partner of GlaxoSmithKline (GSK), for a pandemic H5N1 influenza vaccine.